Pasireotide Research for Neuroendocrine Tumors
An evidence-based overview of research examining Pasireotide in the context of neuroendocrine tumors. This page synthesizes findings from peer-reviewed literature.
Research Summary
Investigated in Phase 2 trials for metastatic NETs progressing on octreotide LAR. Showed antiproliferative activity in some patients. COOPERATE-2 trial evaluated combination with everolimus. Not FDA-approved for this indication but represents area of ongoing research.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Pasireotide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.